Roberts Brigette bought QNCX
May 18, 2026 · Form 4 insider transaction
Roberts Brigette bought 34,675 shares of Quince Therapeutics, Inc., a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 24 days after the transaction.
Footnotes
Received in exchange for a stock option to acquire 50,000 shares of Orphai Therapeutics, LLC ("Orphai") common stock with an exercise price of $0.06 per share pursuant to an Agreement and Plan of Merger, dated May 17, 2026 (the "Merger Agreement"), by and among the Issuer, Phoenix Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("First Merger Sub"), Phoenix Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Second Merger Sub"), Orphai Holdings Therapeutics, Inc., a Delaware corporation ("HoldCo") and Orphai.; Immediately exercisable.